Trends in the treatment of human papillomavirus-associated oropharyngeal carcinoma in Slovakia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F24%3A00079956" target="_blank" >RIV/00209805:_____/24:00079956 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/24:00137095

Výsledek na webu

<a href="https://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=8402&category_id=196&option=com_virtuemart&Itemid=12" target="_blank" >https://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=8402&category_id=196&option=com_virtuemart&Itemid=12</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4149/neo_2024_240306N96" target="_blank" >10.4149/neo_2024_240306N96</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Trends in the treatment of human papillomavirus-associated oropharyngeal carcinoma in Slovakia

Popis výsledku v původním jazyce

The optimal treatment of oropharyngeal cancer (OPC) associated with human papillomavirus (HPV) is currently asubject of clinical research. This questionnaire study investigated current trends in the treatment of HPV-associated (HPV+)OPC in Slovakia with the incorporation of deintensification of oncological treatment into routine clinical practice outsideof clinical trials. The Slovak Cooperative Head and Neck Cancer Group (SCHNCG) developed a questionnaire aimed atidentifying trends in the oncological treatment of HPV+ OPC intended for all radiation oncology (RO) facilities in Slovakia.Specialists in the field of RO responded to general questions about the character of their individual institutions as well asto 4 theoretical clinical scenarios (case reports) regarding the treatment of HPV+ OPC, focusing primarily on the applieddose of radiotherapy (RT), the extent of target volumes, and the type of concurrent chemotherapy (CHT). The questionnairestudy involved 35 RO specialists from 14 institutions in Slovakia. Regarding primary chemoradiotherapy (CRT) in T1N1M0HPV+ OPC, 16 respondents (45.7%) would consider de-escalation of the RT dose to &lt;70 Gy. In the case of postoperativeRT in pT1pN1M0 HPV+ OPC with negative resection margins (R0) and absent extracapsular extension (ECE), 4 physicians(11.4%) would consider de-escalation of the RT dose to &lt;60 Gy in the tumor bed area, while the majority of the treatingspecialists (n=19, 54.3%) would omit concurrent CHT. In the case of primary RT in elderly patient with T2N1M0 HPV+OPC, the same number of physicians (n=16, 45.7%) would consider de-escalation of the RT dose to &lt;70 Gy, and 14 respondents(40.0%) would completely omit CHT. In a high-risk patient with T2N3M0 HPV+ OPC with a complete response after3 cycles of induction chemotherapy (iCHT), none of the respondents would indicate a reduction in the RT dose to the areaof the original tumor and lymphadenopathy to &lt;60 Gy. The doses and extent of irradiated volumes in the treatment of HPV+OPC in Slovakia vary among different institutions. The tendency to de-escalate RT doses and reduce doses of concurrentsystemic therapy in Slovakia is high and there was also an observed trend to reduce the extent of radiation treatment fields.

Název v anglickém jazyce

Trends in the treatment of human papillomavirus-associated oropharyngeal carcinoma in Slovakia

Popis výsledku anglicky

The optimal treatment of oropharyngeal cancer (OPC) associated with human papillomavirus (HPV) is currently asubject of clinical research. This questionnaire study investigated current trends in the treatment of HPV-associated (HPV+)OPC in Slovakia with the incorporation of deintensification of oncological treatment into routine clinical practice outsideof clinical trials. The Slovak Cooperative Head and Neck Cancer Group (SCHNCG) developed a questionnaire aimed atidentifying trends in the oncological treatment of HPV+ OPC intended for all radiation oncology (RO) facilities in Slovakia.Specialists in the field of RO responded to general questions about the character of their individual institutions as well asto 4 theoretical clinical scenarios (case reports) regarding the treatment of HPV+ OPC, focusing primarily on the applieddose of radiotherapy (RT), the extent of target volumes, and the type of concurrent chemotherapy (CHT). The questionnairestudy involved 35 RO specialists from 14 institutions in Slovakia. Regarding primary chemoradiotherapy (CRT) in T1N1M0HPV+ OPC, 16 respondents (45.7%) would consider de-escalation of the RT dose to &lt;70 Gy. In the case of postoperativeRT in pT1pN1M0 HPV+ OPC with negative resection margins (R0) and absent extracapsular extension (ECE), 4 physicians(11.4%) would consider de-escalation of the RT dose to &lt;60 Gy in the tumor bed area, while the majority of the treatingspecialists (n=19, 54.3%) would omit concurrent CHT. In the case of primary RT in elderly patient with T2N1M0 HPV+OPC, the same number of physicians (n=16, 45.7%) would consider de-escalation of the RT dose to &lt;70 Gy, and 14 respondents(40.0%) would completely omit CHT. In a high-risk patient with T2N3M0 HPV+ OPC with a complete response after3 cycles of induction chemotherapy (iCHT), none of the respondents would indicate a reduction in the RT dose to the areaof the original tumor and lymphadenopathy to &lt;60 Gy. The doses and extent of irradiated volumes in the treatment of HPV+OPC in Slovakia vary among different institutions. The tendency to de-escalate RT doses and reduce doses of concurrentsystemic therapy in Slovakia is high and there was also an observed trend to reduce the extent of radiation treatment fields.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/NU22-03-00435" target="_blank" >NU22-03-00435: FMISO-based adaptivní radioterapie nádorů hlavy a krku - prospektivní multicentrická studie</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neoplasma

ISSN

0028-2685

e-ISSN

1338-4317

Svazek periodika

71

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

SK - Slovenská republika

Počet stran výsledku

12

Strana od-do

402-413

Kód UT WoS článku

001335526400009

EID výsledku v databázi Scopus

2-s2.0-85204167573